Myelodysplastic Syndrome Market Outlook and Forecasts 2018 to 2025 and Key Players: Celgene Corporation, Novartis AG and Otsuka, Astellas, Astex, Acceleron Pharma, Onconova Pharmaceuticals, GlaxoSmithKline Plc, Pfizer, Inc., Eli-Lilly and CTI Biopharma

The Global Myelodysplastic Syndrome Treatment Market was valued at US$ 2,213.2 million in 2017 and is projected to expand at a CAGR of 12.7% during the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growing incidence of the bone marrow disorders and cytogenetic abnormalities expected to be the major factor driving growth of the global myelodysplastic syndrome treatment market over the foreseeable future.

Ask Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/775

Myelodysplastic syndrome (MDS) refers to the closely related group of hematopoietic clonal disorders that are majorly observed among the geriatric population. The myelodysplastic syndromes rarely exhibit any symptoms during their earlier stages. Treatments of the MDS usually focuses on either preventing or reducing the complications of the disease with the drug therapies available in the market. This includes Vidaza (Azacitidine), Revlimid (Lenalidomide), Decitabine (Dacogen), and Deferasirox (Jadenu). In cases with extreme impairments of bone marrow, MDS are treated by a bone marrow transplant.

According to a report published in 2015 by American Cancer Society, myelodysplastic syndromes occurs at the rate of 4.8 cases per 100,000 people, which counts up to 13,000 new cases of MDS in the U.S. every year. The report also states that this number has witnessed an increase in the last few years as the average population is ageing every consecutive year. Moreover, the fact report 2014-2015 published by Leukemia and Lymphoma Society suggests that the overall incidence of MDS in the U.S. by gender are 6.7 per 100,000 in male while 3.8 per 100,000 in females.

On the basis of clinical features, peripheral blood and bone marrow findings, cytogenetic analysis that shares features of MDS, and myeloproliferative neoplasms, the World Health Organization (WHO) has classified different types of MDS into:

Chronic myelomonocytic leukemia (CMML-1 and CMML-2)
Atypical chronic myeloid leukemia (CML), Bcr-Abl1 negative
Juvenile myelomonocytic leukemia (JMML)
MDS/MPN, unclassifiable

Talk to Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/775

Primary MDS, which lacks a triggering event, is most commonly found in people suffering from MDS. Repetitive exposure to benzene is considered as one of the causes for this syndrome.

Treatments for MDS include drug therapy using newer agents, blood transfusion, and administration of blood cell growth factors among others. Approved drugs such as Vidaza (Azacitidine), Revlimid (Lenalidomide), Decitabine (Dacogen), and Deferasirox (Exjade) are used for the treatment of symptoms of this syndrome. Vidaza (Azacitidine) was the first drug to receive the U.S. Food and Drug Administration approval for the treatment of MDS. Moreover, this drug was found beneficial in the treatment of both high and low risk patients who are suffering from all subtypes of this syndrome. Key players are focusing on adopting strategies such as product development to gain competitive edge in the market. For instance, Celgene Corporation developed MDS with deletion 5q and post HMA failure with drugs Durvalumab and Luspatercept in the late clinical phases.

Few pipeline drugs that are in phase 2 trials include Durvalumab (PD-L1 Inhibitor), and Luspatercept. The revenue of global MDS market is expected to be driven by the positive outcomes from the clinical trials of many molecules that are in pipeline. Furthermore, in 2016, Opsona Therapeutics Ltd. received orphan drug designation for its OPN-305 humanized IgG4 monoclonal antibody for MDS treatment. Celgene on losing its U.S. exclusivity for Vidaza, generic formulations for Vidaza have entered into the market. The launch of generic version of Vidaza by Natco Pharma in 2017 is also projected to boost growth of myelodysplastic syndrome treatment market.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/775

Key Takeaways of the Myelodysplastic Syndrome Treatment Market:

The global myelodysplastic syndrome treatment market is expected to expand at a CAGR of 12.7% during the forecast period (2016–2025), as there exists a huge potential market, especially in Asia Pacific, Latin America, Middle East, and Africa
Robust development in drug therapies, drugs showing potential in pipeline and inclusion of generic versions of the branded products in the market due to patent expiries are expected to drive the global myelodysplastic syndrome market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.